Haleon Hopes Pathbreaking Eroxon Will ‘Resonate’ With US ED Sufferers

Next month Haleon plc will become the first consumer health company to launch an FDA-approved OTC treatment for erectile dysfunction.

In what it described as a “bold step,” Haleon backed UK R&D firm Futura Medical plc’s drug-free ED gel – approved as a self-care medical device via FDA’s De Novo regulatory pathway – paying $4m in upfront payments, as well as potential commercial and performance-driven sales milestone payments totaling between $5m and $45m over the course of several years